Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000710506 | SCV000228309 | uncertain significance | not provided | 2014-11-19 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000545666 | SCV000652513 | likely benign | Developmental and epileptic encephalopathy, 36 | 2024-12-22 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000710506 | SCV000840742 | uncertain significance | not provided | 2018-02-07 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001192895 | SCV001361340 | uncertain significance | not specified | 2019-07-25 | criteria provided, single submitter | clinical testing | Variant summary: ALG13 c.2975G>A (p.Cys992Tyr) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. 4/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was detected in 7 female individuals at an overall frequency of 3.8e-05 in 183384 control chromosomes, predominantly at a frequency of 0.00024 within the Latino subpopulation in the gnomAD database. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.2975G>A in individuals affected with Epileptic encephalopathy, early infantile, 36 and no experimental evidence demonstrating its impact on protein function have been reported. Two ClinVar submitters (evaluation after 2014) cite the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Revvity Omics, |
RCV000545666 | SCV003826155 | uncertain significance | Developmental and epileptic encephalopathy, 36 | 2021-05-12 | criteria provided, single submitter | clinical testing |